Keybanc maintains Berry (bry) (NASDAQ:BRY) with a Overweight and raises the price target from $12 to $13.
Analyst Bullish On Theseus Pharma’s Platform For Gastric Cancer Therapies
Needham has initiated coverage on Theseus Pharmaceuticals Inc (NASDAQ:THRX) with a Buy rating and a price target of $22. Theseus’ discovery platform…